Incidence of hypomagnesemia in patients with HER2+breast cancer treated with pertuzumab.

被引：0
|
作者：
Shah, Nirja
Daily, Karen Colleen
机构：
[1] Univ Florida, Coll Med, Gainesville, FL USA
[2] Univ Florida, UF Hlth Canc Ctr, Gainesville, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12569
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
    Stephanie Gu
    Stephen Dusza
    Elizabeth Quigley
    Helen Haliasos
    Alina Markova
    Michael Marchetti
    Andrea P. Moy
    Chau Dang
    Shanu Modi
    Diana Lake
    Sarah Noor
    Mario E. Lacouture
    Breast Cancer Research and Treatment, 2024, 203 : 271 - 280
  • [32] Pertuzumab: new hope for patients with HER2-positive breast cancer
    Capelan, M.
    Pugliano, L.
    De Azambuja, E.
    Bozovic, I.
    Saini, K. S.
    Sotiriou, C.
    Loi, S.
    Piccart-Gebhart, M. J.
    ANNALS OF ONCOLOGY, 2013, 24 (02) : 273 - 282
  • [33] Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+Breast Cancer
    Franco-Mateos, Emma
    Souza-Egipsy, Virginia
    Garcia-Estevez, Laura
    Perez-Garcia, Jose
    Gion, Maria
    Garrigos, Laia
    Cortez, Patricia
    Saavedra, Cristina
    Gomez, Patricia
    Ortiz, Carolina
    Cruz, Victor L.
    Ramos, Javier
    Cortes, Javier
    Vega, Juan F.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [34] Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+Breast Cancer
    Shagisultanova, Elena
    Gradishar, William
    Brown-Glaberman, Ursa
    Chalasani, Pavani
    Brenner, Andrew J.
    Stopeck, Alison
    Parris, Hannah
    Gao, Dexiang
    McSpadden, Tessa
    Mayordomo, Jose
    Diamond, Jennifer R.
    Kabos, Peter
    Borges, Virginia F.
    CLINICAL CANCER RESEARCH, 2023, 29 (24) : 5021 - 5030
  • [35] Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+breast cancer
    Iwata, H.
    Yamamoto, N.
    Masuda, N.
    Bando, H.
    Kuroi, K.
    Ohno, S.
    Kasai, H.
    Morita, S.
    Sakurai, T.
    Toi, M.
    BREAST, 2015, 24 : S95 - S95
  • [36] TRASTUZUMAB AND PERTUZUMAB COMBINATION THERAPY ACTIVATES COMPLEMENT-DEPENDENT CYTOTOXICITY AND PHAGOCYTOSIS AGAINST HER2+BREAST CANCER
    Tsao, Li-Chung
    Hartman, Zachary
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A647 - A647
  • [37] Investigation of autoantibodies (AAbs) in HER2+breast cancer (BC) patients treated in the neo-adjuvant setting
    Collins, Denis Martin
    Qiu, Ji
    Blayney, Jaine
    McCabe, Nuala
    Kennedy, Richard
    LaBaer, Joshua
    Crown, John
    CANCER RESEARCH, 2022, 82 (04)
  • [38] Vascular and lymphatic phenotype of HER2+breast cancer
    Tannenbaum, S.
    Rampurwala, M.
    Hegde, P.
    Jabbour, N.
    Phoenix, N.
    Claffey, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Modeling the transcriptome landscape of HER2+breast cancer
    Kalari, Krishna R.
    Chai, High-Seng
    Asmann, Yan W.
    Tang, Xiaojia
    Rossell, David
    Baheti, Saurabh
    Nair, Asha
    Baker, Tiffany R.
    Necela, Brian M.
    Carr, Jennifer M.
    Hart, Steve N.
    Sun, Zhifu
    Kachergus, Jennifer M.
    Younkin, Curtis S.
    Kocher, Jean-Pierre A.
    Thompson, Aubrey E.
    Perez, Edith A.
    CANCER RESEARCH, 2012, 72
  • [40] Characterization of the immune infiltrate in HER2+breast cancer
    Ganesan, Shridar
    Alexe, Gabriela
    Hirshfield, Kim M.
    Yao, Ming
    Bhanot, Gyan
    Deborah, Toppmeyer
    CANCER RESEARCH, 2015, 75
12345